Our group contributed to validate the measurement of the IgA and IgM response to all 23 pneumococcal serotypes (PnPS) present in the polysaccharide vaccine (Pneumovax®) in healthy donors (6), in a wide cohort of patients with Common Variable Immune Deficiencies (CVID) (4), and in children with Transient Hypogammaglobulinemia of Infancy (7). Here, CD79A is linked to common variable immunodeficiency.